• Iain Ross

    Executive Chairman

  • Dominic Jackson


  • Dr Richard Armer


  • Nicholas Adams


  • Dr Matilda Bingham

    Head of Research & Operations

Iain Ross was appointed Non-Executive Chairman of Redx in May 2017 assuming the role of Executive Chairman in October 2017. In addition, he is Chairman of e-Therapeutics plc (AIM:ETX) and Novogen Ltd (ASX: NRT / NASDAQ:NVGN) and also a Non-Executive Director of Anatara LifeSciences Ltd (ASX:ANR). He is a qualified Chartered Director, and a Former Vice Chairman of the Council of Royal Holloway, London University.

Previously, he has held significant roles in multi-national companies including Sandoz, Hoffman La Roche, Reed Business Publishing and Celltech Group plc. He has advised banks and private equity groups on numerous company turnarounds. These include as CEO of Quadrant Healthcare taking the Company public, signing numerous collaborations before selling the business to Elan in 2001. As Chairman and Chief Executive Officer, at Allergy Therapeutics, he re-structured the Company Balance Sheet to position Allergy Therapeutics as a virtually debt free cash generative company prior to its subsequent IPO. As Executive Chairman at Silence Therapeutics Plc (formerly SR Pharma plc), he turned the business around through M&A and established collaborations with Pfizer, Astra Zeneca and Dainippon Sumitomo before completing a merger with Intradigm Inc. He continues to consult for private equity groups on biotech & technology company turnarounds.

Dominic has worked in private equity since 2007 (DIC Europe, Merrill Lynch Global Private Equity and latterly for multiple financial sponsors) and in M&A prior to that (Deutsche Bank, PricewaterhouseCoopers). He has been seconded into portfolio companies as CFO on numerous occasions to stabilise distressed core businesses and implement value initiatives.

Within the healthcare space, Dominic has completed a variety of deals as principal including the £450m sale of IDH to Carlyle, the carve-out and €485m sale of Euromedic’s Dialysis division to Fresenius Medical Care (14x EBITDA), and the refinancing and syndication of €565m term debt tranches within Euromedic’s diagnostic imaging business.  Dominic has extensive situational distressed experience having acquired Peverel (UK’s largest property manager, now Knight Square) for £65m out of administration following which his secondment into the business contributed to its successful turnaround and sequential refinancings with Electra Partners and RBS.  He was also heavily involved in the private equity portfolio of a recent landmark bank work-out as well as the $8bn restructuring of a Middle Eastern sovereign wealth fund.

Dominic qualified as a Chartered Accountant with PricewaterhouseCoopers and is a member of the Chartered Institute of Securities and Investment and the Institute for Turnaround.

Richard Armer joined Redx in 2012, becoming Chief Scientific Officer in 2014. He has significant experience in both small biotechnology and large pharmaceutical companies through his roles within Pfizer, Organon, Ardana, Oxagen, Lectus Therapeutics. Richard’s expertise is in drug discovery with a particular focus on lead optimisation activities, drug disposition, intellectual property and commercial scientific project positioning. He has experience across a wide range of therapeutic areas and has been successful in generating and progressing multiple clinical candidates.

Nicholas Adams joined as the Company’s first Chief Business Officer at the end of 2015. Nick has over 25 years’ experience in the pharmaceutical industry, and in particular in business development. He has led a wide range of deal types, including in- and out-licensing, divestments, royalty buy-outs as well as M&A. He has also worked in clinical development in large and mid-sized pharmaceutical companies and in biotech. Most recently, he was Chief Business Officer of Clavis Pharma ASA, the Norwegian drug development company specialising in oncology. Prior to that, he was Vice President of Business Development at Antisoma Research plc, which developed therapies for cancer and autoimmune disease.

Dr Matilda Bingham has 14 years’ experience in drug discovery and joined the company in 2012. Matilda’s scientific background is in medicinal chemistry having worked at Organon, Schering-Plough and Merck (MSD) before joining the management team at Redx Pharma. Matilda played a key role in setting up the Redx Oncology subsidiary including laboratory design, recruitment, development of health and safety policies and the creation of the current project portfolio. In 2015 she was promoted from Head of Chemistry to Executive Director and currently manages the Cancer and Fibrosis subsidiaries.